Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
Georgios KokolakisRichard Bruce WarrenBruce E StroberAndrew BlauveltLuis PuigAkimichi MoritaMelinda J GooderhamAndreas KörberVeerle VanvoordenMaggie WangDirk de CuyperCynthia MaddenNatalie Nunez GomezMark LebwohlPublished in: The British journal of dermatology (2022)
High proportions of patients who did not adequately respond to adalimumab, ustekinumab or secukinumab achieved high levels of skin clearance after switching to bimekizumab. Bimekizumab was well tolerated and there were no new safety findings.
Keyphrases
- phase iii
- ankylosing spondylitis
- rheumatoid arthritis
- open label
- juvenile idiopathic arthritis
- clinical trial
- disease activity
- double blind
- hidradenitis suppurativa
- phase ii
- ulcerative colitis
- placebo controlled
- coronary artery disease
- early onset
- soft tissue
- high intensity
- systemic lupus erythematosus
- study protocol
- atopic dermatitis